Special Issue "lncRNA and Cancer"
Deadline for manuscript submissions: closed (15 June 2019)
Dr. Kate Lawrenson
Women’s Cancer Program at the Samuel Oschin Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, United States
Website 1 | Website 2 | E-Mail
Interests: The Lawrenson lab explores the factors that drive the deregulation of ovarian cancer transcriptomes. We leverage this insight into gene regulation to understand how inherited and acquired genetic variants contribute to the development of ovarian cancer.
The noncoding genome harbors a complex array of noncoding biofeatures that regulate gene expression and play myriad roles in development and disease. Non-coding RNA is the most abundant non-coding biofeature, and long non-coding RNAs (lncRNAs) have been implicated as critical drivers or suppressors for many tumor types. LncRNAs have diverse functional roles in the cell. Some lncRNAs have been shown to exert local effects on gene expression, whereas others induce large-scale epigenetic remodelling to impact gene expression across a gene locus (e.g. HOTAIR) or whole chromosome (as is the case for XIST in X-chromosome dosage compensation). LncRNAs can also have roles in the post-transcriptional regulation of gene expression, such as MALAT1 in splicing and lincRNA-p21 in translation. LncRNA deregulation in cancer is pervasive, and the overexpression of oncogenic lncRNAs, or the inhibition of tumor suppressive lncRNAs can contribute to neoplasia. In addition, genome-wide association studies have implcated a select handful of lncRNAs as mediators of inherited susceptibility to cancer, and more recently, whole-genome sequencing analyses of tumors have identified somatic variants in lncRNAs that may contribute to the disease process. The functional validation of lncRNAs and lncRNA variants is essential, but challenging, as it is not currently possible to predict lncRNA activity based on transcript sequence alone. In recent years, novel technologies have emerged to allow the detailed mapping of ‘RNA interactomes—the RNA–RNA, RNA–DNA and RNA–protein interactions that characterize a transcript of interest. Cataloguing lncRNA interactomes is providing novel insight into the mechanistic roles of lncRNAs in cancer and will be critical in understanding the role of germline and somatic lncRNA variants associated with cancer.
Dr. Kate Lawrenson
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Long noncoding RNA
- Gene regulation